Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last SFr.101.10 CHF
Change Today +0.70 / 0.70%
Volume 2.5M
NOVN On Other Exchanges
Symbol
Exchange
Xetra
OTC US
SIX Swiss Ex
Frankfurt
As of 11:43 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-reg (NOVN) Snapshot

Open
SFr.100.40
Previous Close
SFr.100.40
Day High
SFr.101.50
Day Low
SFr.100.30
52 Week High
07/20/15 - SFr.103.20
52 Week Low
08/8/14 - SFr.76.05
Market Cap
270.6B
Average Volume 10 Days
4.2M
EPS TTM
SFr.4.02
Shares Outstanding
2.7B
EX-Date
03/3/15
P/E TM
26.0x
Dividend
SFr.2.60
Dividend Yield
2.57%
Current Stock Chart for NOVARTIS AG-REG (NOVN)

novartis ag-reg (NOVN) Details

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company’s Alcon division provides various eye care products, including surgical, ophthalmic pharmaceuticals, and vision care products; ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers generic pharmaceuticals comprising active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or biotechnology-based products; and cytotoxic products for the hospital market, as well as biotech manufacturing services to other companies. The company distributes its OTC products through various channels, such as pharmacies, food, drug, and mass retail outlets. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

120,000 Employees
Last Reported Date: 07/21/15
Founded in 1895

novartis ag-reg (NOVN) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.6.1M
Chief Financial Officer
Total Annual Compensation: SFr.2.6M
President of Institutes for Biomedical Resear...
Total Annual Compensation: $3.0M
Global Head of Novartis Business Services and...
Total Annual Compensation: SFr.1.2M
Division Head of Novartis Pharmaceuticals
Total Annual Compensation: $3.9M
Compensation as of Fiscal Year 2014.

novartis ag-reg (NOVN) Key Developments

Novartis AG Reports Unaudited Consolidated Earnings Results for the Second Quarter and First Half Ended June 30, 2015; Reiterates Earnings Guidance for the Full Year 2015

Novartis AG reported unaudited consolidated earnings results for the second quarter and first half ended June 30, 2015. For the quarter, the company's net sales from continuing operations were $12,694 million compared with $13,411 million a year ago. Operating income from continuing operations was $2,281 million compared with $3,184 million a year ago. This was mainly due to the amortization of the new oncology assets as well as a commercial settlement gain related to intellectual property in the prior-year period, partly offset by strong operating performance. Income before taxes from continuing operations was $2,156 million compared with $3,147 million a year ago. Net income from continuing operations was $1,856 million or $0.76 per diluted share compared with $2,723 million or $1.09 per diluted share a year ago. Net income attributable to shareholders of the company was $1,836 million or $0.75 per diluted share compared with $2,555 million or $1.03 per diluted share a year ago. Total cash flows from operating activities were $2,910 million compared with $3,341 million a year ago. Purchase of property, plant & equipment was $566 million compared with $644 million a year ago. Purchase of intangible, financial and other non-current assets was $476 million compared with $318 million a year ago. Core operating income from continuing operations was $3,593 million compared with $3,859 million a year ago. Core net income from continuing operations was $3,074 million or $1.27 per share compared with $3,335 million or $1.36 per share a year ago. This was due to the lower number of average outstanding shares. Core net income attributable to shareholders of the company was $3,013 million or $1.25 per share compared with $3,253 million or $1.34 per share a year ago. As on June 30, 2015, the company's net debt was $17,399 million. For the six months, the company's net sales from continuing operations were $24,655 million compared with $26,243 million a year ago. Operating income from continuing operations was $5,066 million compared with $5,999 million a year ago. This was mainly due to the amortization of the new oncology assets as well as a commercial settlement gain related to intellectual property in the prior-year period, mostly offset by strong operating performance. Income before taxes from continuing operations was $4,834 million compared with $5,984 million a year ago. Net income from continuing operations was $4,162 million or $1.70 per diluted share compared with $5,177 million or $2.07 per diluted share a year ago. Net income attributable to shareholders of the company was $14,841 million or $6.06 per diluted share compared with $5,496 million or $2.22 per diluted share a year ago. Total cash flows from operating activities were $4,614 million compared with $4,681 million a year ago. Purchase of property, plant & equipment was $1,035 million compared with $1,126 million a year ago. Purchase of intangible, financial and other non-current assets was $722 million compared with $444 million a year ago. Core operating income from continuing operations was $7,244 million compared with $7,659 million a year ago. Core net income from continuing operations was $6,273 million or $2.60 per share compared with $6,668 million or $2.71 per share a year ago. This was due to the lower number of average outstanding shares. Core net income attributable to shareholders of the company was $6,129 million or $2.54 per share compared with $6,438 million or $2.64 per share a year ago. Despite the weaker second-quarter performance, the company reiterated its full-year 2015 guidance. Net sales are still expected to grow in the mid-single digit percentage range at constant exchange rates in the full 2015. Core operating profit is projected to grow ahead of sales at a high-single digit percentage rate at constant exchange rates.

Novartis AG, Q2 2015 Earnings Call, Jul 21, 2015

Novartis AG, Q2 2015 Earnings Call, Jul 21, 2015

Novartis Announces That the US Food and Drug Administration Approves Entresto Tablets

Novartis announced that the US Food and Drug Administration (FDA) has approved Entresto(TM) (sacubitril/valsartan) tablets, previously known as LCZ696, for the treatment of heart failure with reduced ejection fraction. Entresto will be available on prescription for patients whose condition is classified NYHA class II-IV, indicated to reduce the risk of cardiovascular death and heart failure hospitalization. It is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other angiotensin receptor blocker. The FDA's decision is based on results from the 8,442-patient PARADIGM-HF study which was stopped early when it was shown Entresto significantly reduced the risk of cardiovascular death versus ACE-inhibitor enalapril. At the end of the study, patients with reduced ejection fraction who were given Entresto were more likely to be alive and less likely to have been hospitalized for heart failure than those given enalapril. Analysis of safety data showed that Entresto had a similar tolerability profile to enalapril. Entresto is currently undergoing review by Health Authorities around the world, including in Canada, Switzerland and the EU. Once approved by health authorities around the world, Entresto could achieve estimated peak sales in excess of $5 billion for the reduced ejection fraction indication.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVN:VX SFr.101.10 CHF +0.70

NOVN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $334.01 USD +2.86
Amgen Inc $174.50 USD -2.09
Gilead Sciences Inc $118.95 USD +1.09
Johnson & Johnson $99.55 USD -0.66
Nestle SA SFr.73.55 CHF +0.35
View Industry Companies
 

Industry Analysis

NOVN

Industry Average

Valuation NOVN Industry Range
Price/Earnings 26.3x
Price/Sales 4.9x
Price/Book 3.2x
Price/Cash Flow 14.2x
TEV/Sales 4.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-REG, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.